What Saidal Group does

Saidal Group is a state-owned Algerian pharmaceutical industrial group founded in 1982 and listed on the Algiers Stock Exchange since 1999, with 80% government ownership. It is the first and largest generic pharmaceutical manufacturer in Algeria, producing 160 commercialized products across 22 therapeutic classes spanning cardiology, infectiology, diabetology, oncology, and pneumology. The group's core technology stack covers sterile forms (vaccines, insulin pens), solid dosage forms (55 million unit annual capacity at El Harrach), syrups, hormonal and oncology active pharmaceutical ingredients, and rapid diagnostic kits — all operated across 8 production sites and 3 regional distribution centers.

The business operates across three revenue engines: (i) B2B pharmaceutical product sales through ~130 wholesale distributors and direct institutional sales to Algerian public hospitals; (ii) API production and contract manufacturing under technology-transfer partnerships with Novo Nordisk, Roche, Boehringer Ingelheim, Octavius, and IPF; and (iii) fee-for-service bioequivalence testing through the EQUIVAL BIO Center, Algeria's first dedicated bioequivalence facility. Distribution is reinforced by the Saidalyat Saidal proprietary retail pharmacy network of 829 outlets across Algeria. International expansion is being executed via export and technology-transfer MOUs with African nations including Nigeria ($100M), Chad ($50M), Guinea, Tanzania, Rwanda, Libya, Ethiopia, and Belarus, plus institutional engagement with the African Union Commission.

Name

Saidal Group

Legal name

Groupe Industriel SAIDAL Spa

Website

https://saidalgroup.dz

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Saidal Group is Algeria's first and largest state-owned generic pharmaceutical manufacturer, founded in 1982, producing 160 products across 22 therapeutic classes via 8 production sites, 829 retail pharmacies, and a wholesale network serving Algerian public healthcare and exporting to African markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Bioequivalence studies
• Retail pharmacy network

Headquarters

HQ city

Dar El Beïda

HQ country

Algeria

HQ region

Africa

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Saidal generates revenue through the development, production, and commercialization of generic pharmaceutical products. The company markets 160 products across 22 therapeutic classes. Revenue is derived from sales to wholesale distributors, retail pharmacies, and direct institutional sales to hospitals and public health authorities.
2. API/Contract Manufacturing: Saidal produces active pharmaceutical ingredients and contract manufactured products for export and domestic use, including insulins, vaccines, and APIs under technology transfer partnerships with international firms (Novo Nordisk, Roche, Boehringer Ingelheim).
3. Bioequivalence Testing Services: EQUIVAL BIO Center provides bioequivalence and bioavailability study services to pharmaceutical laboratories on a fee-for-service basis, serving as a revenue diversification stream.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Saidal Group develops, produces, and commercializes 160 generic pharmaceutical products across 22 therapeutic classes (cardiology, infectiology, diabetology, oncology, dermatology, pneumology, etc.) through 8 production sites in Algeria. The group operates a vertically integrated model spanning active pharmaceutical ingredient (API) production, finished dosage forms (tablets, capsules, syrups, sterile forms including vaccines and insulin), bioequivalence testing services, and distribution via 3 regional centers, ~130 wholesale distributors, and 829 retail pharmacies under the Saidalyat Saidal brand.

Product overview

Saidal Group is Algeria's leading generic pharmaceutical manufacturer, operating as a unified industrial group specialized in the development, production, and commercialization of pharmaceutical products for human use. The portfolio comprises 160 commercialized generic medications across 22 therapeutic classes (Cardiology, Infectious Diseases, Diabetology, Oncology, Rheumatology, Dermatology, Pneumology, and others). The group operates alongside key supporting services including the Equival Biocenter for bioequivalence studies and the Saidalyat Saidal pharmacy retail network of 829 pharmacies. Recent strategic products include Novo Nordisk insulin pens (Tresiba) and ongoing development of rapid screening kits, cellular therapy clinics, and vaccine manufacturing facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Equival Bio Center (EQB): First center dedicated to bioequivalence studies in Algeria
• Saidal Santé
• Saidalyat Saidal

Products and services

• Generic Pharmaceutical Products A portfolio of 160 generic pharmaceutical products spanning 22 therapeutic classes including cardiology, infectiology, dermatology, diabetology, oncology, pneumology, rheumatology, and others. Products are sold to wholesale distributors, hospitals, and pharmacies across Algeria.
• Tresiba Insulin Pens Latest generation insulin pen injectables produced through partnership with Novo Nordisk, manufactured in full process at Saidal's Constantine facility and available on the Algerian market.
• Saidalyat Saidal Pharmacy Network A nationwide retail pharmacy network of 829 outlets across Algeria under the Saidalyat Saidal brand, providing medication dispensing, free health services, prevention actions, and patient support, organized through 9 regional commercial units.
• Equival Biocenter (EQB) Bioequivalence Studies The first center in Algeria dedicated to bioequivalence studies, providing clinical trials, bioanalysis, and pharmacokinetic data treatment services to pharmaceutical laboratories on a fee-for-service basis.

Quantifiable outcome

• Revenue grew 21.53% to 22.19 billion DZD in 2024
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

23 partnerships are on record, tiered minor and core.

• Sanyou Biopharmaceuticals / Clicklinks PlatformminorOthers · 23 May 2026The Clicklinks platform by Sanyou Biopharmaceuticals is referenced in a news article as a third major platform in their pharma innovation ecosystem. This is an indirect mention and not an active Saidal partnership.
• Republic of Rwanda (Ministry of Health)minorChannel Partner/ Reseller/ Distributor · 10 May 2026Visit by Rwandan ambassador to Saidal exploring cooperation in pharmaceutical industry, with interest in importing Algerian medicines to Rwanda and leveraging Rwanda's central African position for broader regional exports.
• African Union CommissioncoreOthers · 2 April 2026Meeting with African Union Commission representatives (Dr. Adamu Isah, Dr. Diop Mohamed Yahya) to discuss pharmaceutical autonomy in Africa, with focus on supporting Niger. AU expressed satisfaction with Algerian pharmaceutical production quality and pricing.
• Université Djilali Bounaama de Khemis MilianaminorStrategic or Co-development Partner · 9 March 2026Five-year scientific and technical cooperation agreement covering research collaboration, student training, internship programs, and expertise exchange to support innovation and sustainable development of the pharmaceutical sector.
• Bioexpress Therapeutics (Switzerland)coreStrategic or Co-development Partner · 11 January 2026MOU focused on training and skills development in biotechnology with progressive technology transfer to enable local manufacturing of biotechnological products, contributing to national health sovereignty.
• Société Al-Louloua Al-Oula (Libya)minorChannel Partner/ Reseller/ Distributor · 5 October 2025MOU to relaunch exports of pharmaceutical products to Libya and facilitate technology transfer in pharmaceutical production.
• Nigerian Chamber of Commerce and Industry (N-ACCI)coreChannel Partner/ Reseller/ Distributor · 22 September 2025MOU for export of pharmaceutical products worth $100 million to Nigeria, plus technology and know-how transfer. Signed at IATF 2025.
• OMEGA MEDICAL PROMO (Chad)coreChannel Partner/ Reseller/ Distributor · 10 September 2025MOU for export of pharmaceutical products worth $50 million to Chad, plus technology and know-how transfer for development of local pharmaceutical projects in Chad.
• Ordre National des Pharmaciens de Guinée / Chambre de Commerce de GuinéeminorChannel Partner/ Reseller/ Distributor · 9 September 2025MOU for export of Saidal products to Guinea and medium-term development of pharmaceutical projects through technology transfer.
• Tanzanian businessesminorChannel Partner/ Reseller/ Distributor · 9 September 2025Initial export of Saidal products to Tanzania with medium-term plans for technology transfer and support for Tanzania's pharmaceutical development projects.
• AbbVie (represented by Promedex)coreStrategic or Co-development Partner · 2 September 2025MOU for strengthening competencies in bioequivalence and clinical research. AbbVie will support training and professional development of Equival Biocenter staff through certification programs, workshops, and know-how transfer in bioequivalence studies and clinical research.
• Madar HoldingcoreStrategic or Co-development Partner · 9 August 2025Partnership for the construction of a cellular therapy clinic at Sidi Abdellah. Madar Holding provides financing while Saidal contributes expertise, know-how, and technology transfer for stem cell and immune disease treatments.
• RochecoreStrategic or Co-development Partner · 21 July 2025Memorandum of understanding with Swiss biotech leader Roche for manufacturing biotechnological products for treatment of multiple pathologies, notably cancer. Supports Algeria's ambition to become a regional biotech hub.
• Ethiopia (Embassy)minorChannel Partner/ Reseller/ Distributor · 26 June 2025Ethiopian ambassador expressed interest in Saidal investing in Ethiopia, with Ethiopia offering a favorable regulatory framework for Algerian pharmaceutical operators.
• Novo NordiskcoreStrategic or Co-development Partner · 22 June 2025Strategic partnership for production and distribution of insulin products including Tresiba pen injectables. Includes full process insulin manufacturing at Constantine site and progressive introduction of Novo Nordisk's innovative therapeutic solutions for Algerian patients. First commercialized product launched December 2025.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 23 May 2025Strategic agreement for local production of innovative treatment for Idiopathic Pulmonary Fibrosis (IPF). Aligns with national strategy to expand production of innovative medicines.
• Orion LabminorStrategic or Co-development Partner · 20 May 2025Partnership with private Algerian pharmaceutical laboratory based in Oran, signed under the Ministry of Health's 2025 roadmap to strengthen public-private sector cooperation in innovative treatment development and production.
• Democedes Pharma AlgérieminorStrategic or Co-development Partner · 20 May 2025Partnership with private Algerian pharmaceutical laboratory at Aïn M'lila (Oum El Bouaghi) for development and production of innovative treatments, aligned with public-private sector cooperation objectives.
• Université des Sciences et Technologies Houari Boumediene (USTHB)coreStrategic or Co-development Partner · 18 November 2024Strategic partnership for entrepreneurial development and innovation, signed during Global Entrepreneurship Week. Selected among a dozen companies for academic-industry partnerships. Saidal contributes to bridging academia and industry in Algeria.
• IPF (Iran)coreStrategic or Co-development Partner · 6 June 2024Partnership with Iranian IPF for production of paracetamol and acetylsalicylic acid APIs at Batna. Capacity of 2,000 tonnes/year; 675 million DZD investment; 18-month completion with technology transfer.
• AgrodivminorStrategic or Co-development Partner · 18 May 2024MOU signed with Agrodiv for support in manufacturing fermentation-derived products as part of the Phoenix Biotech project at the Médéa facility.
• Iranian Holding Barakat Health CompanycoreStrategic or Co-development Partner · 4 March 2024Contract for production of rapid diagnostic kits at Saidal's Oran site. 85 types of kits planned for human cancer screening, drug testing, plant and animal disease detection. Factory civil works began March 2024 with 8-month delivery target.
• Octavius Pharma (India)coreStrategic or Co-development Partner · 8 February 2024Partnership for production of pharmaceutical raw materials (antibiotics) at the Médéa factory. Resumption of a facility idle for 15+ years with 750 tonnes/year capacity. Production to start June 2024; initial focus on domestic market with surplus for export.

Scale indicators12 records

Recent moves14 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: Largest specialty generic pharmaceutical company in India and one of the largest globally, with emerging market presence. Comparable on generic manufacturing scale and therapeutic class breadth; broader incumbent than Saidal but uses similar partnership models in emerging markets.
• Aurobindo Pharma: Major Indian generic pharmaceutical manufacturer with extensive global distribution including Africa. Comparable on vertically integrated API-to-finished dosage manufacturing and aggressive emerging market expansion strategy.

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical company with significant MENA and US operations. Comparable to Saidal on generic manufacturing scale, regional distribution networks, and stated ambition to serve emerging markets including Africa.
• Cipla: Indian generic pharmaceutical major with one of the largest African footprints, including manufacturing/distribution in South Africa and partnerships across the continent. Closely comparable to Saidal on generic drug manufacturing, multi-country African distribution, and partnership-driven capability building.
• Eva Pharma: Egyptian pharmaceutical manufacturer with broad generic portfolio across therapeutic categories, strong North and sub-Saharan African presence, and ambition to become a regional hub. Comparable to Saidal on product breadth, African export focus, and EM pharma positioning.
• Julphar (Gulf Pharmaceuticals): UAE-based generic pharmaceutical manufacturer with MENA manufacturing footprint and export markets. Comparable on generic manufacturing, regional distribution, and government-backed industrial positioning.
• Pharco Pharmaceuticals: Major Egyptian pharmaceutical company with broad generic and branded portfolio and significant MENA presence. Comparable on North African manufacturing scale, therapeutic class breadth, and focus on affordable medicines.
• Aspen Pharmacare: Largest pharmaceutical manufacturer in Africa (South Africa-headquartered), producing generics, specialty, and consumer health products across the continent. Closely comparable on Africa-focused manufacturing, multi-country distribution, and partnership-driven capability expansion.
• EIPICO: Egyptian generic pharmaceutical manufacturer with broad therapeutic portfolio and African export focus. Comparable to Saidal on North African manufacturing base, generic product portfolio across multiple therapeutic classes, and emerging market positioning.

Regional players

• Adcock Ingram: South African pharmaceutical manufacturer with generic, OTC, and consumer health portfolio serving primarily Southern Africa. Comparable on African pharma manufacturing, multi-category portfolio, and emerging market distribution dynamics, though focused on a different sub-region than Saidal.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/groupesaidal

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saidal Group